# Skyrizi (risankizumab-rzaa) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/risankizumab-rzaa

> The FDA approved Skyrizi (risankizumab-rzaa), sponsored by AbbVie Inc. (ABBV), on June 16, 2022.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Skyrizi (risankizumab-rzaa) |
| Codes |  |
| Sponsor | AbbVie Inc. (ABBV) https://sec-api.dev/companies/abbv/catalysts |
| Indications |  |
| Modality | biologic |
| FDA designations | priority review |

## Timeline

### April 23, 2019: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761105 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20190423, review_priority STANDARD; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761105%22

### April 26, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761105 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20210426, review_priority STANDARD; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761105%22
- openFDA Drugs@FDA: "BLA761105 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20210426, review_priority STANDARD; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761105%22

### January 21, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761105 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20220121, review_priority STANDARD; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761105%22

### June 16, 2022: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761262 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20220616, review_priority PRIORITY; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761262%22

### June 16, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761105 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20220616, review_priority PRIORITY; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761105%22

### September 23, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761105 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20220923, review_priority STANDARD; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761105%22

### June 18, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761262 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20240618, review_priority STANDARD; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761262%22
- openFDA Drugs@FDA: "BLA761105 SUPPL-29 (Efficacy): submission_status AP, submission_status_date 20240618, review_priority STANDARD; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761105%22

### September 3, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761262 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20250903, review_priority STANDARD; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761262%22
- openFDA Drugs@FDA: "BLA761105 SUPPL-39 (Efficacy): submission_status AP, submission_status_date 20250903, review_priority STANDARD; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761105%22

### March 6, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761105 SUPPL-42 (Efficacy): submission_status AP, submission_status_date 20260306, review_priority STANDARD; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761105%22

### June 12, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761105 SUPPL-44 (Efficacy): submission_status AP, submission_status_date 20260612, review_priority STANDARD; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761105%22

### June 26, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761105 SUPPL-45 (Efficacy): submission_status AP, submission_status_date 20260626, review_priority STANDARD; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761105%22

### October 23, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761105 SUPPL-53 (Efficacy): submission_status AP, submission_status_date 20261023, review_priority PRIORITY; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761105%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/risankizumab-rzaa.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Skyrizi (risankizumab-rzaa) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/risankizumab-rzaa

```bibtex
@misc{secapidev_pdufa_risankizumab_rzaa_20261116,
  title        = {Skyrizi (risankizumab-rzaa) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/risankizumab-rzaa}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_risankizumab_rzaa_20261116","title":"Skyrizi (risankizumab-rzaa) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/risankizumab-rzaa","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
